biostudies-literatureHe PPostgraduate Innovation project of Hunan University of Chinese MedicineHunan Provincial Natural Science Foundation Youth ProjectHunan Provincial Education Department Outstanding Youth ProjectKey guidance topics of Hunan Provincial Health CommissionNational Natural Science Foundation of China1819https://www.ebi.ac.uk/biostudies/studies/S-EPMC11545145biostudies-literatureUnknown13(21)Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its prevention and treatment face severe challenges. It is crucial to improve the targeting of drugs on tumor cells and tissues. Celastrol (CeT), as an active ingredient of traditional Chinese medicine, possesses strong antitumor effects, especially in triggering apoptosis of HCC. However, due to its toxicity and lack of targeting, its application is greatly limited. HMCLPs, a nano-biomimetic platform carrying CeT with controllable drug release, enhanced targeting, and immunocompatibility, were developed for the first time, which can be used for the treatment of HCC. By utilizing homologous cell membranes and hyaluronic acid (HA), HMCLPs can precisely target tumor regions and release CeT in a CellsCelastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention.PMC11545145No.202213055529No.2023CX143No. 82274159No.2023JJ40485No.23B0387Qin LZou MZhang CHe PShi YfalseCelastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention.Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its prevention and treatment face severe challenges. It is crucial to improve the targeting of drugs on tumor cells and tissues. Celastrol (CeT), as an active ingredient of traditional Chinese medicine, possesses strong antitumor effects, especially in triggering apoptosis of HCC. However, due to its toxicity and lack of targeting, its application is greatly limited. HMCLPs, a nano-biomimetic platform carrying CeT with controllable drug release, enhanced targeting, and immunocompatibility, were developed for the first time, which can be used for the treatment of HCC. By utilizing homologous cell membranes and hyaluronic acid (HA), HMCLPs can precisely target tumor regions and release CeT in a 2024-01-01T00:00:00Z2024 Nov2025-04-04T18:56:20.408Z2025-04-04T18:56:20.408ZS-EPMC115451453951392510.3390/cells13211819